Drug · CHEMBL1908360
EVEROLIMUS
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. EVEROLIMUS. Drugs and targets, record CHEMBL1908360. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL1908360
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- 40-o-(2-hydroxyethyl)-rapamycin, 42-o-(2-hydroxyethyl)rapamycin, RAD 666, RAD-001, RAD-666, RAD001, Rapamycin, 42-o-(2-hydroxyethyl)-, SDZ-RAD, Sdz rad
- ChEMBL
- Open Targets' highest stage
- Approval, for 12 of its 201 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | FK506-binding protein 1A inhibitor | INHIBITOR | https://conductscience.org/library/genes/2280 |
Source ChEMBL
Diseases201
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| breast cancer | Approval | DailyMed | 112 | 110 | https://conductscience.org/library/drugs?q=MONDO_0007254 |
| renal cell carcinoma | Approval | DailyMed, EMA Human Drugs, PMDA and TTD | 62 | 55 | https://conductscience.org/library/drugs?q=MONDO_0005086 |
| neuroendocrine neoplasm | Approval | DailyMed | 25 | 24 | https://conductscience.org/library/drugs?q=MONDO_0019496 |
| non-small cell lung carcinoma | Phase 2 | ClinicalTrials.gov | 20 | 20 | https://conductscience.org/library/drugs?q=MONDO_0005233 |
| prostate cancer | Phase 3 | ClinicalTrials.gov | 19 | 19 | https://conductscience.org/library/drugs?q=MONDO_0008315 |
| pancreatic neuroendocrine tumor | Phase 3 | ClinicalTrials.gov | 15 | 15 | https://conductscience.org/library/drugs?q=MONDO_0019954 |
| colorectal cancer | Phase 2 | ClinicalTrials.gov | 13 | 13 | https://conductscience.org/library/drugs?q=MONDO_0005575 |
| cancer | Phase 2 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0004992 |
| endometrial cancer | Phase 2 | ClinicalTrials.gov | 12 | 12 | https://conductscience.org/library/drugs?q=MONDO_0011962 |
| kidney cancer | Phase 3 | ClinicalTrials.gov and TTD | 12 | 11 | https://conductscience.org/library/drugs?q=MONDO_0002367 |
1 to 10 of 201Source Open Targets
See all 201 diseasesTrials813
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 2 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01589978 | PROMUS Element Plus US Post-Approval Study | Phase 4 | 2,681 | 2016-05-03 | everolimus | Its name | ClinicalTrials.gov |
| NCT01950819 | Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) | Phase 4 | 2,037 | 2019-01-30 | everolimus | Its name | ClinicalTrials.gov |
| NCT01674140 | S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer | Phase 3 | 1,939 | 2023-12-20 | everolimus | Its name | ClinicalTrials.gov |
| NCT01120249 | S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery | Phase 3 | 1,545 | 2024-03-20 | everolimus | Its name | ClinicalTrials.gov |
| NCT00823212 | The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions | Phase 3 | 1,530 | 2012-01-27 | everolimus | Its name | ClinicalTrials.gov |
| NCT03468478 | Comparison of the Efficacy and Safety of Sirolimus Versus Everolimus Versus Mycophenolate in Kidney Transplantation | Phase 4 | 1,209 | 2023-04-24 | everolimus | Its name | ClinicalTrials.gov |
| NCT02811861 | Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma | Phase 3 | 1,069 | 2021-09-24 | everolimus | Its name | ClinicalTrials.gov |
| NCT00251004 | Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients | Phase 3 | 833 | 2011-05-10 | everolimus | Its name | ClinicalTrials.gov |
| NCT01114529 | Efficacy, Safety and Evolution of Cardiovascular Parameters in Renal Transplant Recipients | Phase 3 | 828 | 2017-05-30 | everolimus | Its name | ClinicalTrials.gov |
| NCT01668784 | Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | Phase 3 | 821 | 2016-04-29 | everolimus | Its name | ClinicalTrials.gov |
1 to 10 of 813
See all 813 trialsComparisons in its trials207
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| EVR+rCNI vs MPA+sCNI: Incidence of Adverse Events, Serious Adverse Events and Adverse Events Leading to Study Regimen Discontinuation. | 276 of 1,014 | 152 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| EVR+rCNI vs MPA+sCNI: Incidence of Major Cardiovascular Events. | 66 of 1,014 | 86 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: deaths from any cause | 20 of 1,014 | 29 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| EVR+rCNI vs MPA+sCNI: Incidence of Malignancies. | 41 of 1,014 | 39 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus Plus@Reduced CNI vs MPA Plus Standard@CNI: serious adverse events | 593 of 1,014 | 613 of 1,012 | 2,026 | NCT01950819 | Trial comparisons |
| Everolimus vs Placebo: deaths from any cause | 112 of 896 | 119 of 896 | 1,792 | NCT01674140 | Trial comparisons |
| Everolimus vs Placebo: serious adverse events | 180 of 874 | 77 of 881 | 1,755 | NCT01674140 | Trial comparisons |
| PROMUS vs PROMUS Element: serious adverse events | 237 of 762 | 238 of 768 | 1,530 | NCT00823212 | Trial comparisons |
| Everolimus vs Placebo: deaths from any cause | 139 of 755 | 151 of 744 | 1,499 | NCT01120249 | Trial comparisons |
| Everolimus vs Placebo: serious adverse events | 154 of 740 | 68 of 723 | 1,463 | NCT01120249 | Trial comparisons |
1 to 10 of 207
See all 207 comparisons in its trialsPapers from its trials497
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials11
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Rapid Visual Information Processing | 2 | 1 | ConductCognition |
| Tower Planning | 2 | 2 | ConductCognition |
| Cancellation Test | 1 | 0 | ConductCognition |
| Complex Figure Copy and Recall | 1 | 1 | ConductCognition |
| Continuous Performance Test | 1 | 0 | ConductCognition |
| Intra/Extra Dimensional Set Shift | 1 | 1 | ConductCognition |
| Pattern Recognition Memory | 1 | 1 | ConductCognition |
| Spatial Recognition Memory | 1 | 1 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
| Verbal Learning | 1 | 0 | ConductCognition |
1 to 10 of 11
See all 11 tests in its trialsData dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL1908360
GET https://conductscience.org/api/drugs/v1/CHEMBL1908360/diseases?page=2